United States. Securities and Exchange Commission
The Boston Beer Company, Inc., a Massachusetts-based brewery, has filed a Form 8-K report with the U.S. Securities and Exchange Commission stating that Michael M. Lynton, a member of the company's board of directors, will not stand for re-election at the end of his current term. Lynton&
United States. Securities and Exchange Commission
Amgen Inc., a biopharmaceutical company, has made a significant filing with the U.S. Securities and Exchange Commission (SEC) on March 9, 2023, through Form 8-K, the "current report" used to disclose material events or corporate changes. This filing was made available to the public through the SEC&
United States. Securities and Exchange Commission
Caribou Biosciences, Inc., a biotechnology company, has reported a material event through a U.S. Securities and Exchange Commission (SEC) filing. The filing, submitted on March 9, 2023, reveals a significant occurrence that affects investors or security holders. This event is detailed in a "current report" submitted using
United States. Securities and Exchange Commission
According to a recent SEC filing, Amgen Inc. disclosed a significant update related to the company's leadership and corporate structure. The filing, submitted on March 8, 2023, provides insight into the company's compliance with US securities regulations. As a major biopharmaceutical company, Amgen Inc. is subject
United States. Securities and Exchange Commission
A U.S. Securities and Exchange Commission (SEC) filing by Seagen Inc. on March 3, 2023, revealed a notable disclosure. The SIC code for this company is 2836, Biological Products, specifically excluding Diagnostic Substances. As per the SEC filing, Seagen Inc.'s contact information is 21823 30TH DRIVE SE,
United States. Securities and Exchange Commission
As of March 10, 2023, Astra Space, Inc. (Astra) has around 15% of its current cash, cash equivalents, and marketable securities held on deposit with Silicon Valley Bank (SVB), which was recently closed by the California Department of Financial Protection and Innovation. The bank's closure has raised substantial
United States. Securities and Exchange Commission
Sangamo Therapeutics, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on March 10, 2023, in response to the closure of Silicon Valley Bank by the California Department of Financial Protection and Innovation. The bank was appointed as receiver by the Federal Deposit Insurance Corporation
United States. Securities and Exchange Commission
Voyager Therapeutics, Inc. has announced the appointment of Jude Onyia, Ph.D. as a director of the company, contingent upon the closing of a collaboration and license agreement with Neurocrine Biosciences, Inc. Dr. Onyia, who has served as Chief Scientific Officer of Neurocrine since November 2021, will serve on Voyager&
United States. Securities and Exchange Commission
As part of a broader probe into workplace misconduct allegations, the US Securities and Exchange Commission (SEC) has found Activision Blizzard, Inc. to have failed in maintaining adequate disclosure controls and violating an SEC whistleblower protection rule. The company has agreed to pay a $35 million settlement, marking the end
United States. Securities and Exchange Commission
Neurocrine Biosciences Inc., a leading biopharmaceutical company, recently filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on February 6, 2023. This filing reported a series of material events and corporate changes of importance to investors and security holders. As a current report, the Form 8-K
United States. Securities and Exchange Commission
A U.S. Securities and Exchange Commission (SEC) filing by Fate Therapeutics Inc. was posted on February 7, 2023. The company, operating in the biopharmaceutical industry, submitted a single document with form 4, which reports on transactions involving directors, officers, and major shareholders. This filing is a requirement for companies
United States. Securities and Exchange Commission
According to a recent SEC filing, Fate Therapeutics Inc., a biopharmaceutical company, has submitted a report to the U.S. Securities and Exchange Commission on January 11, 2023. The company, which specializes in biological products, has reported one document filed with the form. This filing is a requirement for publicly-traded
